Data From Phase 1 Clinical Trial of PDX (Pralatrexate) to be Presented at American Society of Hematology Annual Meeting
16 11월 2005 - 10:00PM
PR Newswire (US)
WESTMINSTER, Colo., Nov. 16 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) today announced that preliminary
data from a Phase 1 study evaluating the Company's novel antifolate
PDX has been accepted for presentation at the American Society of
Hematology's 47th Annual Meeting, to be held December 10 - 13 in
Atlanta. Owen O'Connor, M.D., Ph.D., Attending Physician,
Department of Medicine, Memorial Sloan-Kettering Cancer Center, is
scheduled to report preliminary observations from an on-going Phase
1 study of PDX in patients with relapsed or refractory aggressive
lymphoproliferative malignancies in a poster presentation titled
"Pralatrexate (10-Propargyl-10-Deazaaminopterin (PDX)), a Novel
Antifolate, Effects Durable Complete Remissions (CR) in Patients
With a Diversity of Drug Resistant T-Cell Lymphomas with Minimal
Toxicity." on Sunday, December 11. A copy of the abstract is
currently available on the American Society of Hematology's web
site, http://www.hematology.org/. About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (NASDAQ:ALTH) is a biopharmaceutical
company focused on developing and commercializing innovative small
molecule therapeutics for the treatment of cancer. Our lead product
candidate, EFAPROXYN(TM) (efaproxiral), is a synthetic small
molecule designed to sensitize hypoxic, or oxygen-deprived, tumor
tissue during radiation therapy. EFAPROXYN is currently being
evaluated as an adjunct to whole brain radiation therapy in a
pivotal Phase 3 trial in women with brain metastases originating
from breast cancer. Our other product candidates are: PDX
(pralatrexate), a small molecule chemotherapeutic agent (DHFR
inhibitor) currently under investigation as both a single agent and
in combination therapy regimens in patients with non-small cell
lung cancer and Non-Hodgkin's lymphoma; and RH1, a small molecule
chemotherapeutic agent bioactivated by the enzyme DT-diaphorase
currently under evaluation in patients with advanced solid tumors.
For more information, please visit the Company's web site at:
http://www.allos.com/. Safe Harbor Statement The anticipated
presentation will contain forward-looking statements that involve
significant risks and uncertainties, including those to be
discussed in the presentation and others that can be found in the
"Risk Factors" section of the Company's Form 10-K for the year
ended December 31, 2004 and in the Company's periodic reports on
Form 10-Q and Form 8-K. The Company does not undertake any
obligation to update any forward-looking statements contained in
the anticipated presentation as a result of new information, future
events or otherwise. The Company cautions investors not to place
undue reliance on the forward-looking statements contained in the
presentation. No forward-looking statement can be guaranteed and
actual events and results may differ materially from those
projected. DATASOURCE: Allos Therapeutics, Inc. CONTACT: Jennifer
Neiman, Manager, Corporate Communications, of Allos Therapeutics,
+1-720-540-5227, Web site: http://www.hematology.org/ Web site:
http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Allos Therapeutics (MM) News Articles